Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The occurrence of bone loss in Crohn's disease patients is an important clinical problem for
both patients with and without active disease. While therapy does exist for treatment and
prevention of low BMD, evidence of its efficacy in Crohn's disease patients is lacking. The
current standard of therapy in Canada for the treatment of osteoporosis is etidronate, with
adequate calcium and vitamin D supplementation.
The primary objective of the study is to assess the efficacy of risedronate, compared to
placebo, administered once-weekly, in the treatment of low BMD of the spine and hip in
patients with Crohn's disease at 12 months, based on an intention-to-treat analysis.
Phase:
Phase 4
Details
Lead Sponsor:
University of Alberta
Treatments:
Etidronic Acid Risedronate Sodium Risedronic Acid Vitamin D Vitamins